Cash price for popular weight loss drug Wegovy dropping 30% Monday, manufacturer says

Novo Nordisk said it will cut the U.S. cash price for its GLP-1 drugs Wegovy and Ozempic by 30% to $349 per month from $499, effective Monday at about 70,000 retail pharmacies including Walmart and Costco; the move lowers costs for uninsured and self-pay customers and previously matched the cash price of Eli Lilly’s Zepbound full dose. The company framed the reduction as part of a broader access strategy—working with telehealth providers, major retailers, payers and the U.S. administration to expand coverage and affordability—which could intensify pricing and access dynamics across the competitive GLP-1 market.

Analysis

Novo Nordisk announced a 30% reduction in the U.S. cash price for its GLP-1 drugs Wegovy and Ozempic to $349 per month from $499, effective Monday at roughly 70,000 retail pharmacies including Walmart and Costco. The reduction targets uninsured and self-pay customers and replaces a prior cash price that matched Eli Lilly's Zepbound full dose.

The company described the move as part of a broader access strategy, with executive vice president Dave Moore pointing to savings offers, partnerships with telehealth providers and major retailers, and engagement with the U.S. administration to expand coverage for obesity and type 2 diabetes. Lower out-of-pocket costs are likely to reduce initiation friction for self-pay patients and could accelerate prescription starts in the near term.

The tactical consequences are competitive and margin-based: the price cut undercuts prior parity with Lilly, raising the probability of a pricing or access response from competitors and payers and creating downward pressure on per-unit realizations even if volumes rise. Market signals in the dataset show moderately positive sentiment toward NVO and a negative tilt for LLY; investors should therefore watch gross-to-net dynamics, reimbursement behavior and early volume/coverage datapoints to determine if higher volumes offset lower cash pricing.

Key Decisions for Investors

• Consider increasing selective exposure to NVO to capture improved affordability and positive sentiment, but size positions conservatively until gross-to-net and margin effects are quantified
• Reduce or hedge exposure to LLY given elevated competitive pressure on Zepbound pricing and the article's negative sentiment signal, and monitor for any prompt pricing or access response from Lilly
• Monitor pharmacy rollout metrics, telehealth partnership uptake and insurer coverage changes over the next 1-2 quarters as leading indicators of whether lower cash pricing translates into sustainable revenue growth